Effect of Tadalafil on Endometrial Thickness and Frozen Embryo Transfer Outcomes

What this Trial Is About

Researchers are evaluating the effects of different vasodilators, specifically Tadalafil, on women experiencing unexplained infertility who are undergoing in vitro fertilization (IVF). This study involves women aged 18 to 43 years who have good quality day five frozen embryos and aims to understand how Tadalafil influences endometrial thickness and pregnancy outcomes following frozen embryo transfer. The research is a prospective, randomized clinical trial approved by the Ethical Committee at Beni Suef University Hospitals in Egypt. Participants are randomly assigned into two groups. The control group receives estradiol valerate 2 mg tablets, starting with one pill three times daily, which may be increased based on endometrial thickness measured by vaginal ultrasound on day 9. The experimental group receives the same estradiol valerate treatment plus a daily dose of Tadalafil 5 mg starting from the first day of the cycle until the day progesterone treatment begins. Both treatments are studied in parallel to assess their effects. Throughout the study, all patients undergo detailed history taking, general and laboratory examinations including hormone levels (AMH, FSH, LH, estradiol, prolactin, and TSH), and ultrasound imaging. The primary outcome measured is pregnancy status one month after treatment. The trial monitors the participants closely from the start of the cycle through embryo transfer and early pregnancy evaluation, with all procedures conducted under ethical approval and informed consent.

Effect of Tadalafil on Endometrial Thickness and Frozen Embryo Transfer Outcomes